Armistice Capital’s Bristol-Myers Squibb BMY Stock Holding History

Armistice Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.5M	Buy	233,790 +28,766	+14%	+$1.65M	0.16%	86
2026 Q1	$12.4M	Sell	205,024 -167,442	-45%	-$9.76M	0.22%	81
2025 Q4	$20.1M	Sell	372,466 -277,267	-43%	-$13.3M	0.24%	71
2025 Q3	$29.3M	Buy	+649,733	New	+$30.3M	0.43%	34
2024 Q3	–	Sell	-490,868	Closed	-$20.4M	–	265
2024 Q2	$20.4M	Buy	+490,868	New	+$22M	0.26%	66
2023 Q4	–	Sell	-529,613	Closed	-$30.7M	–	311
2023 Q3	$30.7M	Buy	529,613 +129,613	+32%	+$7.94M	0.47%	42
2023 Q2	$25.6M	Buy	+400,000	New	+$26.8M	0.37%	53
2022 Q4	–	Sell	-600,000	Closed	-$42.7M	–	202
2022 Q3	$42.7M	Sell	600,000 -556,000	-48%	-$40.3M	0.74%	36
2022 Q2	$89M	Sell	1,156,000 -240,000	-17%	-$18.3M	1.55%	12
2022 Q1	$102M	Sell	1,396,000 -928,000	-40%	-$62.3M	1.97%	9
2021 Q4	$145M	Sell	2,324,000 -32,000	-1%	-$1.88M	2.37%	4
2021 Q3	$139M	Buy	2,356,000 +678,000	+40%	+$44.7M	2.36%	4
2021 Q2	$112M	Buy	1,678,000 +178,000	+12%	+$11.6M	2.01%	6
2021 Q1	$94.7M	Buy	1,500,000 +464,000	+45%	+$28.9M	2.17%	4
2020 Q4	$64.3M	Buy	1,036,000 +36,000	+4%	+$2.21M	2.19%	7
2020 Q3	$60.3M	Hold	1,000,000	–	–	2.19%	8
2020 Q2	$58.8M	Buy	1,000,000 +352,000	+54%	+$21.1M	2.58%	5
2020 Q1	$36.1M	Buy	648,000 +148,000	+30%	+$9.05M	2.23%	12
2019 Q4	$32.1M	Buy	+500,000	New	+$28.6M	1.85%	13

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Armistice Capital's BMY Position: Q2 2026 in Review

Armistice Capital increased its Bristol-Myers Squibb (BMY) stake by 14% in Q2 2026, buying an estimated $1.65M and bringing the position to 233,790 shares worth $13.5M. The position accounts for 0.16% of the portfolio, ranked #86.

Armistice Capital first reported a position in BMY in Q4 2019 and has held it in 19 quarters since. The position peaked at $145M in Q4 2021. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Armistice Capital held 233,790 shares of Bristol-Myers Squibb worth $13.5M as of Q2 2026.
Armistice Capital bought 28,766 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.65M.
Bristol-Myers Squibb made up 0.16% of Armistice Capital's portfolio in Q2 2026, its #86 holding.
Armistice Capital first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 19 quarters since.
Armistice Capital's Bristol-Myers Squibb position peaked at $145M in Q4 2021.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.